Title
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Medications That May Trigger Drug-Induced Lupus: What You Should Know

Written By

Why This Was Updated?

Our specialists regularly review advancements in health and wellness, ensuring our articles are updated with the newest information as it becomes accessible.
Medically Reviewed by
Dr.
Ayesha Bryant
MSPH, MD

Drug-induced lupus (DIL) is a condition where certain medications may trigger symptoms that resemble those of lupus, an autoimmune disease. Unlike systemic lupus erythematosus (SLE), DIL may be triggered by specific medications and typically improves once the medication is discontinued. While it’s not very common, it can be confusing and uncomfortable for those who experience it.

Understanding which medications might trigger DIL and recognizing the signs can help you and your healthcare provider address the symptoms quickly. In this article, we’ll explore the medications commonly associated with drug-induced lupus, what symptoms to watch for, and how DIL differs from other forms of lupus.

[signup]

Understanding Drug-Induced Lupus (DIL)

Drug-induced lupus (DIL) is caused directly by a reaction to a specific medication and typically resolves after the medication is stopped. It's a temporary, reversible condition that primarily affects the joints, muscles, and skin. 

While the exact mechanisms behind DIL aren't completely understood, it is believed to involve the immune system becoming overly reactive in response to certain medications. When certain drugs enter the body, they may trigger an autoimmune response. 

This means the immune system may mistakenly attack the body’s own tissues, leading to inflammation and lupus-like symptoms.

The development of DIL can vary from person to person, as not everyone taking a specific medication will experience this reaction. Genetics, environmental factors, and the medication’s specific properties all play a role in whether or not someone develops DIL.

How Can Medications Lead to Autoimmunity?

Some medications may trigger DIL because they can impact the immune system in ways that potentially promote autoimmunity. These include drugs that are used to treat high blood pressure, infections, heart rhythm problems, or even inflammatory conditions. 

For example, certain medications may increase inflammation or alter how immune cells function, prompting the body to create antibodies that attack its own cells. These antibodies can then lead to the symptoms associated with drug-induced lupus.

Symptoms and Diagnosis

The symptoms of DIL are similar to those seen in other types of lupus but are generally considered milder. They include: 

  • Joint pain and swelling
  • Muscle pain
  • Fever
  • Fatigue
  • A skin rash, which may worsen with sun exposure
  • Chest pain

In general, symptoms develop gradually and can appear anywhere from a few weeks to several years after starting a medication.

Diagnosing Drug-Induced Lupus

Diagnosing DIL can be challenging, as its symptoms overlap with many other autoimmune conditions, including SLE. However, there are some differences. DIL generally lacks severe symptoms associated with SLE, such as kidney and nervous system involvement.

To confirm a diagnosis, healthcare providers will take a detailed history of medication use and conduct blood tests. These tests may show specific autoantibodies, like anti-histone antibodies, which are commonly associated with DIL.

Recognizing DIL early can make a big difference in treatment and outcomes. Once the suspected medication is stopped, symptoms usually improve within weeks to months. Early diagnosis and proper management can help prevent complications and provide relief from uncomfortable symptoms. 

Always work closely with your healthcare provider if you suspect any medication-related side effects, as they can guide you through testing, diagnosis, and treatment steps effectively.

What Are the 38 Drugs That Cause Drug-Induced Lupus?

While there are many medications that can trigger drug-induced lupus (DIL), a number of them are more commonly linked to this condition. Note that not everyone who takes these medications will develop DIL, as it depends on individual factors like genetics, dosage, and duration of treatment.

Key Medications Linked to DIL

Below is a list of 38 drugs that have been associated with DIL, grouped by their categories.

Antiarrhythmics (for heart rhythm disorders)

Antihypertensives (for high blood pressure)

Antibiotics/Antifungals

Anticonvulsants (for seizures and mood disorders)

Antithyroid Drugs (for thyroid disorders)

Immunomodulators and Biologics (for autoimmune and inflammatory conditions)

Other Drugs

Mechanisms of Action

Medications linked to DIL may impact the immune system in several ways, potentially promoting an autoimmune response. Some may alter how immune cells function, increase inflammation, or lead to the creation of specific autoantibodies that attack healthy cells. For instance:

  • Procainamide and Hydralazine are believed to cause the body to produce certain autoantibodies, such as anti-histone antibodies, which are commonly seen in DIL.
  • Genetic predisposition: Certain genetic factors make some people more susceptible to developing DIL. These may include specific genes involved in drug metabolism or immune system regulation.
  • Dosage and treatment duration: Higher doses and long-term use of medications significantly raise the risk of DIL. For example, patients on high doses of procainamide for extended periods are more likely to develop lupus-like symptoms.

Risk Factors for Developing Drug-Induced Lupus

Drug-induced lupus (DIL) doesn't affect everyone who takes the medications associated with it. Certain patient and medication-specific factors can raise the risk of developing this condition. Understanding these risk factors can help both patients and healthcare providers make informed decisions about treatment options.

Patient Factors

  1. Age: DIL can occur at any age, but it’s more commonly seen in older adults, as they are often prescribed medications that have the potential to trigger this condition. Younger individuals are not exempt but may have a lower overall risk.
  1. Gender: DIL, like other forms of lupus, tends to be more common in females. This may be related to hormonal differences that influence immune system function. Women are generally at higher risk of autoimmune conditions in general, including drug-induced ones.
  1. Genetic Predisposition: Some people are more likely to develop DIL based on their genetic makeup. For example, certain genes influence how the body metabolizes medications, affecting the likelihood of triggering an autoimmune response. Individuals with a family history of autoimmune conditions may also have a higher risk.
  1. Medication Dose and Duration: The risk of DIL often depends on how much of the medication you take and for how long. High doses of certain drugs and prolonged use (over months to years) are strongly associated with an increased risk of developing DIL. For example, medications like procainamide and hydralazine are more likely to cause DIL when taken in larger doses over a long period.

Medication-Specific Risks

Not all medications carry the same risk of causing DIL. Some are well-known offenders, while others carry a moderate or lower risk. Understanding the likelihood of DIL with each medication can help manage and monitor potential symptoms effectively.

Drugs Associated with High Risk for DIL

  • Procainamide: This antiarrhythmic drug carries a high risk of DIL, with up to 20-30% of long-term users potentially developing symptoms. The risk increases with higher doses and extended treatment.
  • Hydralazine: Often used to treat high blood pressure, hydralazine has a strong association with DIL. Patients taking more than 200 mg per day are at a higher risk, particularly if the treatment duration is long.
  • Isoniazid: A medication used to treat tuberculosis, it can trigger DIL in some patients, particularly those who take it for prolonged periods.

Drugs Associated with Moderate Risk for DIL:

  • Quinidine: While also an antiarrhythmic like procainamide, quinidine carries a moderate risk for DIL. The incidence is lower than that of procainamide, but the potential still exists.
  • Minocycline: A commonly prescribed antibiotic for acne and infections, minocycline has been associated with DIL but to a lesser extent compared to drugs like hydralazine and procainamide.
  • Phenytoin and Carbamazepine: These anticonvulsants, used to treat seizures, are known to carry some risk for DIL. However, their association with DIL is generally considered moderate.

Factors Affecting Medication-Specific Risks

  • High Cumulative Dose: The total amount of medication taken over time plays a big role in the development of DIL. Medications like procainamide and hydralazine show a clear link between dose and risk.
  • Slow Acetylators: Individuals who metabolize drugs more slowly (referred to as “slow acetylators”) are at higher risk for DIL. This is because the medication remains in the body longer, increasing the potential for immune system activation.

Managing and Treating Drug-Induced Lupus

When drug-induced lupus (DIL) is suspected or diagnosed, management primarily focuses on stopping the causative medication. Fortunately, with timely intervention, many patients may experience significant improvement and may recover fully. Let’s explore the steps for managing and treating DIL, including medication discontinuation, symptom relief, and long-term outlook.

Stopping the Medication

The first and most important step in managing DIL is stopping the medication that triggered the lupus-like symptoms. Unlike other types of lupus, DIL is directly caused by a specific drug, so removing that trigger is usually highly effective. Your healthcare provider will help identify which medication is causing the issue and, if possible, provide an alternative treatment.

Most patients notice significant improvement in their symptoms within weeks of stopping the offending medication. Full resolution of symptoms often occurs within several weeks to months, but this timeline may vary. 

For example, joint pain and muscle aches may lessen within weeks, while skin rashes might take a bit longer to clear up. It's important to note that the timeline for symptom relief can vary depending on the drug involved and individual patient factors like overall health and duration of medication use.

Symptomatic Treatment

While stopping the medication is key, supportive treatments are often used to manage symptoms and improve comfort during recovery.

Anti-Inflammatory Treatments

  • NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): For mild symptoms such as joint pain, fever, and muscle aches, over-the-counter anti-inflammatory medications like ibuprofen or naproxen can be helpful. These medications work to reduce inflammation and provide pain relief.
  • Corticosteroids: For patients with more significant inflammation or more severe symptoms, corticosteroids like prednisone may be prescribed. They are highly effective in reducing inflammation but are generally used only for a short period until symptoms improve.

Monitoring and Managing Severe Cases

While most cases of DIL are mild, some patients may experience more severe symptoms, such as pleuritis (inflammation of the lining of the lungs), pericarditis (inflammation around the heart), or more significant joint swelling. 

These patients require closer monitoring and may need more aggressive anti-inflammatory treatments or specialty care. Severe cases are rare but underscore the importance of recognizing DIL early and working closely with a healthcare provider for proper management.

Long-Term Outlook

The prognosis for patients with drug-induced lupus is generally very favorable. Once the offending medication is stopped, symptoms generally resolve without lasting damage. Unlike systemic lupus erythematosus (SLE), DIL rarely causes long-term organ involvement or serious complications.

For most patients, symptoms disappear completely after the medication is discontinued, and the immune system resets. However, the timeline for complete resolution can vary:

  • Mild symptoms (like joint pain and rash) may improve within weeks to months.
  • In rare cases, some symptoms can persist for longer periods, but they generally continue to improve over time.

Recurrence of DIL is generally unlikely if the causative drug is avoided. However, if a patient is re-exposed to the same medication or a similar drug in the future, there's a risk of developing DIL again.

Prevention and Best Practices for Healthcare Providers

While drug-induced lupus (DIL) is a temporary and manageable condition, healthcare providers play an essential role in preventing its onset and ensuring the well-being of patients on medications that may trigger it. This includes careful patient selection, regular monitoring, and patient education to help identify DIL early and avoid unnecessary complications.

Screening and Monitoring Patients

When prescribing medications known to cause DIL, it's important to assess each patient’s risk factors. Patients should be informed about what to watch for, including potential symptoms such as joint pain, muscle aches, fevers, skin rashes, and general malaise. Clear instructions on when to contact a healthcare provider if symptoms arise can lead to faster diagnosis and treatment.

Regular Monitoring

For patients who must be on drugs known to trigger DIL, regular monitoring is vital. The goal is to identify any early signs of lupus-like symptoms or other concerning changes before they progress. The frequency of monitoring may vary depending on the medication, the patient's risk level, and any existing symptoms.

Alternatives to High-Risk Drugs

For patients at higher risk of developing DIL, considering alternative medications can help reduce the likelihood of triggering this condition. When deciding on an alternative treatment, healthcare providers should weigh the benefits and risks of available options. Here are some strategies:

  • Switching to Lower-Risk Medications: If a patient is at high risk for DIL or has started developing mild symptoms, switching to a different medication class with a lower association with DIL may be recommended. For example, if hydralazine is causing symptoms, other antihypertensive agents with less risk for DIL might be explored.
  • Lower Doses and Shorter Duration: If alternative medications aren't an option, using the lowest effective dose for the shortest possible time may decrease the risk of developing DIL.

Healthcare providers should consider collaborating with specialists (e.g., rheumatologists) when treating patients with complex conditions that require medications known to trigger DIL. Specialist input may be valuable for adjusting medications, monitoring for symptoms, or selecting safer alternatives.

[signup]

Key Takeaways

  • Drug-Induced Lupus (DIL) is a reversible condition triggered by certain medications, primarily affecting joints, muscles, and skin, and typically resolves once the causative drug is discontinued.
  • Medications commonly associated with DIL include antiarrhythmics like procainamide, antihypertensives such as hydralazine, certain antibiotics, anticonvulsants, and biologics, with higher doses and prolonged use potentially increasing the risk.
  • Symptoms of DIL are often milder than systemic lupus erythematosus (SLE) and may include joint pain, muscle aches, fever, fatigue, and rashes; they typically develop gradually and improve within weeks to months after stopping the medication.
  • Risk factors for developing DIL include genetic predisposition, higher age, female gender, medication dose, and duration, with individuals who metabolize drugs slowly being at higher risk.
  • Management of DIL focuses on stopping the offending medication and providing symptomatic relief through anti-inflammatories like NSAIDs or corticosteroids, with most patients experiencing a favorable prognosis and full symptom resolution over time.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No lab tests!

Alpha Interferon. (2018, May 4). Nih.gov; National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK547867/

Blomgren, S. E., Condemi, J. J., & Vaughn, J. H. (n.d.). Procainamide-induced lupus erythematosus.

BORCHERS, A. T., KEEN, C. L., & GERSHWIN, M. E. (2007). Drug-Induced Lupus. Annals of the New York Academy of Sciences, 1108(1), 166–182. https://doi.org/10.1196/annals.1422.019

Choi, J., & Fenando, A. (2020). Sulfasalazine. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557809/

Cloyd, J. (2023, March 7). An integrative medicine approach to fatigue. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-fatigue

Drug-induced lupus erythematosus: MedlinePlus Medical Encyclopedia. (2016). Medlineplus.gov. https://medlineplus.gov/ency/article/000446.htm

Ellis, C. R., & Azmat, C. E. (2020). Adalimumab. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557889/

Faruqi, A., & Jain, A. (2022, November 6). Enalapril. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557708/

Fatima, R., Bittar, K., & Aziz, M. (2020). Infliximab. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK500021/

Grant, D. M., Mörike, K., Eichelbaum, M., & Meyer, U. A. (1990). Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. Journal of Clinical Investigation, 85(3), 968–972. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC296518/

Gupta, A., & Rehman, A. (2020). Propylthiouracil (PTU). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK549828/

Gupta, M., & Al Khalili, Y. (2020). Methyldopa. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK551671/

Gupta, M., & Tripp, J. (2023). Phenytoin. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK551520/

Haidary, H. A., & Padhy, R. K. (2023, November 10). Clozapine. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK535399/

Hanoodi, M., & Mittal, M. (2023, January 16). Methotrexate. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK556114/

Hanrahan, B., & Carson, R. P. (2019, October 3). Ethosuximide. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK544244/

He, Y., & Sawalha, A. H. (2018). Drug-induced lupus erythematosus. Current Opinion in Rheumatology, 1. https://doi.org/10.1097/bor.0000000000000522

Heart Inflammation - Pericarditis | NHLBI, NIH. (2023, October 10). Www.nhlbi.nih.gov. https://www.nhlbi.nih.gov/health/heart-inflammation/pericarditis

Herman, L. L., & Tivakaran, V. S. (2023). Hydralazine. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470296/

Hunter, M. P., & Regunath, H. (2020). Pleurisy. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558958/

Iyer, P., Dirweesh, A., & Zijoo, R. (2017). Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody. Case Reports in Rheumatology, 2017, 5245904. https://doi.org/10.1155/2017/5245904

Jain, A., & Sisodia, J. (2020). Quinidine. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK542193/

John Hopkins Medicine. (2023). Lupus Risk Factors. Www.hopkinsmedicine.org. https://www.hopkinsmedicine.org/health/conditions-and-diseases/lupus/lupus-risk-factors

Kasturi, S., & Sammaritano, L. R. (2016). Corticosteroids in Lupus. Rheumatic Disease Clinics of North America, 42(1), 47–62. https://doi.org/10.1016/j.rdc.2015.08.007

Khakham, C. (2023, July 21). Integrative and Complementary Approach to Drug-Induced Lupus: Testing, Nutrition, and Supplements. Rupa Health. https://www.rupahealth.com/post/integrative-and-complementary-approach-to-drug-induced-lupus-testing-nutrition-and-supplements

Kronzer, V. L., Bridges, S. L., & Davis, J. M. (2020). Why women have more autoimmune diseases than men: an evolutionary perspective. Evolutionary Applications, 14(3). https://doi.org/10.1111/eva.13167

Lahita, R. G., & Shao, C. (2016, January 1). Chapter 59 - Nonsteroidal Anti-inflammatory Drugs in Systemic Lupus Erythematosus (G. C. Tsokos, Ed.). ScienceDirect; Academic Press. https://www.sciencedirect.com/science/article/abs/pii/B9780128019177000590

Lee, A. Y. S. (2022). Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus. Immunological Medicine, 1–6. https://doi.org/10.1080/25785826.2022.2060168

Lupus Foundation of America. (2018). What is drug-induced lupus? Lupus Foundation of America. https://www.lupus.org/resources/about-drug-induced-lupus

Maan, J. S., & Saadabadi, A. (2023). Carbamazepine. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482455/

Maidhof, W., & Hilas, O. (2012). Lupus: an overview of the disease and management options. P & T : A Peer-Reviewed Journal for Formulary Management, 37(4), 240–249.

Mann, S. K., & Marwaha, R. (2023, May 16). Chlorpromazine. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK553079/

Marte, F., & Cassagnol, M. (2022, January 21). Captopril. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK535386/

Maxfield, L., Preuss, C. V., & Bermudez, R. (2020). Terbinafine. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK545218/

McCormack, G. D., & Barth, W. F. (1985). Quinidine induced lupus syndrome. Seminars in Arthritis and Rheumatism, 15(1), 73–79. https://doi.org/10.1016/0049-0172(85)90012-5

Mejias, S. G., & Ramphul, K. (2020). Penicillamine. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK513316/

Motta, E., Kazibutowska, Z., Lorek, A., Januszewski, K., Gołba, A., & Wianecka, A. (2006). [Carbamazepine-induced systemic lupus erythematosus--a case report]. Neurologia I Neurochirurgia Polska, 40(2), 151–155. https://pubmed.ncbi.nlm.nih.gov/16628512/#:~:text=Epileptic%20seizures%20may%20be%20an

Nazarian, S., & Akhondi, H. (2022). Minocycline. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554519/

O’Connor, C., & Brady, M. F. (2022, April 8). Isoniazid. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557617/

Om Talreja, & Manouchkathe Cassagnol. (2023, August 28). Diltiazem. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532937/

Orbeta, R. (2022, April 1). 8 Signs And Symptoms Of An Autoimmune Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-autoimmune-disease

Padda, I. S., & Goyal, A. (2021). Leflunomide. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557799/

Pan, A., & Gerriets, V. (2020). Etanercept. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK545252/

Prevention, I. of M. (US) B. on H. P. and D. (1997). Genetic Factors Affecting Development of Autoimmunity. In www.ncbi.nlm.nih.gov. National Academies Press (US). https://www.ncbi.nlm.nih.gov/books/NBK232995/

Pritchard, B., & Thompson, H. (2020). Procainamide. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557788/

Qurie, A., Pankaj Bansal, Amandeep Goyal, & Musa, R. (2019, December 26). Allopurinol. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499942/

Rahman, M., & Nguyen, H. (2023). Valproic Acid (Divalproex Sodium). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559112/

Schlienger, R. G., Bircher, A. J., & Meier, C. R. (2000). Minocycline-induced lupus: a systematic review. Www.ncbi.nlm.nih.gov; Centre for Reviews and Dissemination (UK). https://www.ncbi.nlm.nih.gov/books/NBK68209/

Singh, G., & Correa, R. (2020). Methimazole. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK545223/

Solhjoo, M., Bansal, P., Goyal, A., & Chauhan, K. (2020). Drug-Induced Lupus Erythematosus. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK441889/

Squadrito, F. J., & Del Portal, D. (2023). Nitrofurantoin. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470526/

Sundjaja, J. H., & Makaryus, A. N. (2021). Disopyramide. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557434/

Vaghela, J. H., Solanki, Y., Lakhani, K., & Purohit, B. (2019). Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report. Drug Safety - Case Reports, 6(1). https://doi.org/10.1007/s40800-019-0102-y

Vaglio, A., Grayson, P. C., Fenaroli, P., Gianfreda, D., Boccaletti, V., Ghiggeri, G. M., & Moroni, G. (2018). Drug-induced lupus: Traditional and new concepts. Autoimmunity Reviews, 17(9), 912–918. https://doi.org/10.1016/j.autrev.2018.03.016

Varghese, D., & Haseer Koya, H. (2023). Polypharmacy. National Library of Medicine; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532953/

Xiao, X., & Chang, C. (2013). Diagnosis and classification of drug-induced autoimmunity (DIA).

Yoshimura, H. (2023, May 8). A Functional Medicine Systemic Lupus Erythematosus (SLE) Protocol: Testing, Diagnosing, and Treatment. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-systemic-lupus-erythematosus-sle-protocol-testing-diagnosing-and-treatment

Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
See All Magazine Articles
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
National Library of Medicine
Government Authority
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
National Cancer Institute
Government Authority
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
CDC
Government Authority
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
National Institutes of Health
Government Authority
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Brain
Peer Reviewed Journal
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Chest
Peer Reviewed Journal
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source